首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1321834

癌症免疫（IO）治療藥物的全球市場（2023-2030）：按藥物類型、應用和生物標誌物劃分的規模和份額□增長分析/預測

Global Immuno-Oncology Drugs Market Size, Share, Growth Analysis, By Type of drugs(Monoclonal antibodies, checkpoint inhibitors), By Application(Lung cancer, breast cancer), By Biomarker(PD-L1, BRCA) - Industry Forecast 2023-2030

出版日期: 2023年07月16日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球免疫腫瘤（IO）治療市場規模預計將從2021年的603.2億美元增長到2022年的705.7億美元，預測期內復合年增長率為17%，到2030年將達到24.78億美元。增長至2000萬美元。

提高生存率、減少副作用、個性化治療、長期緩解的潛力以及新的治療選擇是 IO 藥物的一些好處。IO 療法優於化學療法和放射療法等傳統癌症療法，因為它們能夠精確靶向癌細胞。此外，由於其密集性質，IO 藥物不會以同樣的方式影響健康細胞，這使得它們對患者的危害比傳統治療更小。

監管部門的批准為全球 IO 治療市場提供了利潤豐厚的增長機會。由於監管部門的批准，IO 療法的市場已顯著擴大。歐洲藥品管理局（EMA）和美國食品藥品監督管理局（FDA）等監管機構大大提高了藥品的安全性和有效性。在批准一種藥物用於臨床之前，當局會審查臨床試驗的結果並權衡該藥物的利弊。市場增長的一個關鍵因素是新的IO藥物獲得監管機構的批准。

生物標誌物的創建已成為 IO 治療市場的重要趨勢。新型生物標誌物的創建是 IO 治療市場的一個重要研究領域，因為它可以實現更準確的患者選擇並改善治療結果。

本報告調查了全球免疫腫瘤（IO）治療藥物市場，並提供了市場概況、市場各種影響因素分析、技術和創新趨勢、法律和監管環境、市場規模趨勢和預測以及各種分類。 - 地區分佈、競爭狀況、主要公司概況等摘要。

AbbVie Inc.
Amgen Inc.
AstraZeneca plc
Biogen Inc.
Bristol Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc
Incyte Corporation
Merck &Co., Inc.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Sanofi SA
Seattle Genetics, Inc.
Takeda Pharmaceutical Company Limited
Tesaro, Inc.
Xencor, Inc.
Y-mAbs Therapeutics, Inc.

簡介目錄

Product Code: SQMIG35I2108

Global Immuno-Oncology Drugs Market size was valued at USD 60.32 billion in 2021 and is poised to grow from USD 70.57 billion in 2022 to USD 247.82 billion by 2030, growing at a CAGR of 17% in the forecast period (2023-2030).

Increased survival rates, decreased side effects, personalized treatment, the possibility of long-term remission, and new therapeutic choices are just a few of the benefits of immuno-oncology drugs. Due to their capacity to target cancer cells precisely, immuno-oncology (IO) medications have a distinct edge over conventional cancer treatments like chemotherapy and radiation therapy. Due to their focused nature, IO medicines have less adverse effects on patients than conventional treatments since they do not affect healthy cells in the same way. Top-down and bottom-up approaches were used to estimate and validate the size of Immuno-Oncology Drugs and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report:

The market for immuno-oncology medications is divided into segments based on drug type, application, biomarker, and region. The market is divided into Lung cancer, Breast cancer, Prostate cancer, Melanoma, and others based on application. The market is divided into monoclonal antibodies, checkpoint inhibitors, cancer vaccines, cytokines, cell treatments, and others based on the type of drug being used. The market is divided into PD-L1, BRCA, KRAS, EGFR, and other biomarkers. North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America are the different geographic segments

Driver

Regulatory Approvals to Bring Lucrative Growth Opportunities for Players in the Global Immuno-Oncology Drug Market

The market for immuno-oncology (IO) therapies is expanding significantly as a result of regulatory agencies' approval of IO medications. For IO therapies to be marketed and utilized in clinical practice, regulatory approval is necessary, and the approval of new drugs is a good sign for the market for IO drugs. Drug safety and effectiveness are greatly enhanced by regulatory organizations like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Before approving a medicine for use in clinical practice, authorities review the findings of clinical studies and weigh the advantages and disadvantages of the drug. An important factor in the market's growth is the regulatory authorities' approval of new IO medications.

Restraints

High Cost to Hinder Market Growth

The high price of immuno-oncology (IO) medications is one of the factors that can potentially impede the market's expansion. IO medications frequently cost a lot of money, and both patients and medical professionals may find it difficult to afford the cost of therapy. The adoption of IO medications may be constrained by their high price, especially in nations with limited access to affordable healthcare, which could have a detrimental effect on the market's expansion. The high cost of IO medications may also have an impact on how willing insurance providers and public healthcare systems are to pay for medical expenses, which may further restrict patient access to these medications.

Market Trends

The creation of biomarkers is a significant trend in the immuno-oncology (IO) therapeutic market. In order to pinpoint certain patient traits that increase their likelihood of responding to IO medicines, biomarkers are used. By utilizing biomarkers, doctors are better able to determine which patients require IO therapies, as well as to evaluate the effectiveness of the therapy and modify the course of action as necessary. The creation of novel biomarkers is a key area of research in the market for IO drugs since it can result in more accurate patient selection and better treatment outcomes. The creation of biomarkers is a significant trend in the immuno-oncology (IO) therapeutic market. In order to pinpoint certain patient traits that increase their likelihood of responding to IO medicines, biomarkers are used.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Immuno-Oncology Drugs Market by Type of drugs

Market Overview
Monoclonal antibodies
checkpoint inhibitors
cancer vaccines
cytokines
cell therapies
and others

Global Immuno-Oncology Drugs Market by Application

Market Overview
Lung cancer
breast cancer
prostate cancer
melanoma and others

Global Immuno-Oncology Drugs Market by Biomarker

Market Overview
PD-L1
BRCA
KRAS
EGFR
and others

Global Immuno-Oncology Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seattle Genetics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tesaro, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Xencor, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Y-mAbs Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments